FedHealthIT
PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance and Exchange (IPGE) for real-world data, today announced that Michael J. Cavanagh, President and Chief Financial Officer of Comcast Corporation, and Dr. Raquel Bono, Chief Health Officer of Viking, have been appointed to its board of directors.
Cavanagh brings decades of exceptional expertise in guiding high growth businesses to the HealthVerity board. In his role at Comcast Corporation, he has a broad range of responsibilities, including overseeing all financial functions, corporate development, strategic planning, and corporate administration. Cavanagh joined Comcast in 2015 after spending more than 20 years in the financial services industry at companies like JPMorgan Chase and The Carlyle Group.
A board-certified trauma surgeon and retired Vice Admiral of the United States Navy Medical Corps, Dr. Bono most recently led Washington State’s medical and healthcare systems response to the COVID-19 pandemic. She saw duty in Operations Desert Shield and Desert Storm and is the first female Navy medical officer to have achieved three-star rank. As CEO and Director for the Defense Health Agency (DHA), Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel.
“Mike Cavanagh is one of the most accomplished strategic financial leaders in corporate America and will bring strong capital markets and corporate governance expertise to the company,” said Andrew Kress, CEO of HealthVerity. “His participation on the Board will significantly enhance the value that we offer to our Pharmaceutical Manufacturer, Insurance and Government clients.”
“Dr. Bono’s decorated military service, broad organizational leadership and unique healthcare insights will be a tremendous asset to the company and we are honored to welcome her to the Board,” said Kress. “Her experience and counsel will be critical as we enter the next phase of our journey to bring critical infrastructure to the healthcare insights economy.”
Cavanagh earned a B.A. from Yale University and a J.D. from the University of Chicago. He serves on the Board of Trustees of Yale and is Chairman of its Investment Committee. Cavanagh is also a member of the Council on Foreign Relations.
Dr. Bono earned a B.A. from the University of Texas at Austin and M.D. from the School of Medicine at the Texas Tech University Health Sciences Center. She also holds an MBA from the Carson College of Business at Washington State University, is a Diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons and a Senior Fellow with the Johns Hopkins University Applied Physics Laboratory. Her personal decorations include a Defense Distinguished Service Medal, three Defense Superior Service Medals, three Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation Medals.
“I am excited to be joining the HealthVerity Board at such an important moment in the company’s growth and believe that the organization is well positioned to continue to help its clients recognize the best return on investment in their data strategies,” said Cavanagh.
“I am delighted to join the HealthVerity team and look forward to contributing to the company’s technological approach to solving some of the most difficult challenges in healthcare,” said Dr. Bono.
With these appointments, Cavanagh and Bono will complement HealthVerity’s seasoned management team, an experienced board of directors and accomplished founders with extensive experience across healthcare and technology.
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.
Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com
Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.
PHL INNO
Forbes
PR Newswire
PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced that it has been awarded a contract with the Centers for Disease Control and Prevention (CDC) to provide a large-scale, fully interoperable, real-world dataset to advance a wide range of COVID-19 research, decision making, and public health impact objectives. Using Privacy-Preserving Record Linkage (PPRL), the HealthVerity data asset securely links de-identified patient-level data across medical and pharmacy claims, chargemaster, electronic medical records, and lab data, including genomic sequencing of COVID-19 variants, to generate comprehensive and longitudinal patient histories without sharing personally identifiable information.
The goal of this contract is to provide the CDC with a real-world dataset that is uniquely suited to provide novel insights into new and emerging priority questions related to SARS-CoV-2 variants, vaccinations, testing, re-infection, health impact, natural history, and the long-term effects of COVID-19. The data has high impact potential for CDC’s COVID-19 response and surveillance efforts because it offers CDC scientists the opportunity to conduct complex analyses and develop use cases on disease patterns, progression, and health outcomes. Leveraging its HealthVerity IPGE platform, including the nation’s largest privacy-protected healthcare and consumer data ecosystem, HealthVerity is assembling the largest, fully interoperable, real-world COVID-19 data asset ever acquired by the CDC.
“HealthVerity is proud to support the CDC in leveraging strategic data assets on its quest to understand the broad impact of COVID-19 on patients, healthcare systems, and communities,” said Andrew Kress, CEO at HealthVerity. “We are pleased that our expertise in patient identity resolution and privacy management combined with the broad cross-sectional healthcare and consumer data we manage on behalf of our data partners uniquely enables us to deliver a level of dimensionality for evidence generation that is critical to this major public health endeavor.”
In addition to COVID-19, the agreement provides the CDC with access to timely and comprehensive data on other key therapeutic areas such as viral hepatitis and HIV and the impact on key demographic groups, all in a privacy-protected, HIPAA-compliant manner.
HealthVerity has a history of serving key governmental health agencies to support public health initiatives. Most recently, HealthVerity supported the National Cancer Institute (NCI) for a groundbreaking study of SARS-CoV-2 antibodies in February 2021, announced a research contract with the U.S. Food and Drug Administration (FDA) to support COVID-19 clinical study and treatment opportunities in June 2020 and was awarded a PPRL contract for COVID-19 vaccine data with the Department of Health and Human Services (HHS) in November 2020.
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.
Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com
Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.
PHILADELPHIA, PA — (PRNewswire) — Today HealthVerity announced an agreement with Janssen Research & Development, LLC (Janssen) to provide access to the HealthVerity IPGE platform, the largest linked real-world data ecosystem in the US, to further facilitate critical research and development activities. Prior work between HealthVerity and Janssen in data science highlights a broad set of R&D use cases, including:
“We’ve seen the need for real-time RWD to increase dramatically in the wake of COVID-19. The use of this data will continue to accelerate with the expanded focus on RWD to support research and development and regulatory decision making,” said Andrew Kress, CEO at HealthVerity. “In order to support this shift, our clients and data partners need us to help solve the challenge of how to apply this data at scale in a transformative way. The HealthVerity Identity, Privacy, Governance and Exchange (IPGE) platform provides access to record-level data, giving our clients the flexibility to run their own cutting-edge RWE and Data Science analytics and applications on numerous projects at once. We are pleased to collaborate with Janssen’s leading-edge R&D Data Science organization to put this capability into practice.”
The HealthVerity IPGE platform, integrated technology and RWD infrastructure – driven by identity, privacy, governance and exchange – enables organizations to connect and directly access the largest de-identified and privacy-compliant linked real-world dataset of 330 million US patients across the broadest network of data sources, including Medical and Pharmacy Claims, Electronic Health Records (EHR), Labs and Consumer data. The integrated multi-modal linkage capabilities of RWD to clinical trial patients allows the creation of longitudinal patient journeys supporting numerous use cases including Long Term Follow Up (LTFU) and Phase 4 studies.
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.
Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com
Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.
Technical.ly
Philadelphia Business Journal
